文献速递糖尿病

试验期间维生素D暴露与糖尿病前期成人新发糖尿病:D2d研究二次分析

Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study.
PubMed 文献 · Diabetes Care · 2020-10-05

该二次分析基于D2d研究,比较每日补充100 μg(4000单位)维生素D3与安慰剂对糖尿病前期成人新发糖尿病的影响。试验期间维生素D暴露以年度血清25(OH)D累积滚动均值计算。结果显示,试验分组与试验期间25(OH)D水平存在交互作用(交互P=0.018);在维生素D组中,维持25(OH)D≥100 nmol/L者糖尿病风险显著低于维持50-74 nmol/L者。

要点

  • 维生素D组中,试验期间25(OH)D每升高25 nmol/L,糖尿病风险比为0.75(95%CI 0.68-0.82)。
  • 维生素D组维持25(OH)D 100-124 nmol/L者糖尿病风险比为0.48(95%CI 0.29-0.80)。
  • 维生素D组维持25(OH)D≥125 nmol/L者糖尿病风险比为0.29(95%CI 0.17-0.50)。

核心结论

  • 每日补充维生素D使血清25(OH)D维持≥100 nmol/L,可能有助于降低糖尿病前期成人的糖尿病风险。

研究设计与样本

  • D2d研究为随机对照试验,比较每日补充100 μg(4000单位)维生素D3与安慰剂对糖尿病前期成人新发糖尿病的影响。
  • 本分析为二次分析,试验期间维生素D暴露以年度血清25(OH)D测量的累积滚动均值计算。

主要发现

  • 试验分组与试验期间25(OH)D水平在预测糖尿病风险上存在交互作用(交互P=0.018)。
  • 维生素D组中,试验期间25(OH)D每升高25 nmol/L,糖尿病风险比为0.75(95%CI 0.68-0.82)。
  • 安慰剂组中,试验期间25(OH)D每升高25 nmol/L,糖尿病风险比为0.90(95%CI 0.80-1.02)。
  • 维生素D组中,维持25(OH)D 100-124 nmol/L者糖尿病风险比为0.48(95%CI 0.29-0.80),维持≥125 nmol/L者为0.29(95%CI 0.17-0.50),均以维持50-74 nmol/L者为参照。

关键数值与推荐

  • 参照范围为试验期间25(OH)D 50-74 nmol/L,即美国国家医学院认为充足的范围内。

临床怎么用

  • 对糖尿病前期成人补充维生素D时,可将试验期间血清25(OH)D维持在≥100 nmol/L作为潜在目标以减少糖尿病风险。

局限性

  • 本研究为D2d研究的二次分析,随机后偏倚可能影响补充维生素D在糖尿病预防试验中的疗效估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Postrandomization biases may influence the estimate of efficacy of supplemental vitamin D in diabetes prevention trials. In the Vitamin D and Type 2 Diabetes (D2d) study, repeated measures of serum 25-hydroxyvitamin D [25(OH)D] level provided an opportunity to test whether intratrial vitamin D exposure affected diabetes risk and whether the effect was modified by trial assignment (vitamin D vs. placebo). RESEARCH DESIGN AND METHODS: The D2d study compared the effect of daily supplementation with 100 μg (4,000 units) of vitamin D3 versus placebo on new-onset diabetes in adults with prediabetes. Intratrial vitamin D exposure was calculated as the cumulative rolling mean of annual serum 25(OH)D measurements. Hazard ratios for diabetes among participants who had intratrial 25(OH)D levels of <50, 75-99, 100-124, and ≥125 nmol/L were compared with those with levels of 50-74 nmol/L (the range considered adequate by the National Academy of Medicine) in the entire cohort and by trial assignment. RESULTS: There was an interaction of trial assignment with intratrial 25(OH)D level in predicting diabetes risk (interaction P = 0.018). The hazard ratio for diabetes for an increase of 25 nmol/L in intratrial 25(OH)D level was 0.75 (95% CI 0.68-0.82) among those assigned to vitamin D and 0.90 (0.80-1.02) among those assigned to placebo. The hazard ratios for diabetes among participants treated with vitamin D who maintained intratrial 25(OH)D levels of 100-124 and ≥125 nmol/L were 0.48 (0.29-0.80) and 0.29 (0.17-0.50), respectively, compared with those who maintained a level of 50-74 nmol/L. CONCLUSIONS: Daily vitamin D supplementation to maintain a serum 25(OH)D level ≥100 nmol/L is a promising approach to reducing the risk of diabetes in adults with prediabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Dawson-Hughes B, Staten MA, Knowler WC, et al. Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study. Diabetes Care. 2020. PMID: 33020052. doi:10.2337/dc20-1765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。